Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATINO Study: Pegasys + Copegus in HCV Genotype 1
NCT00107653Phase 4Completed
- Sponsor
- Roche
- Start
- Oct 2004
- Primary completion
- Sep 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Roche. Primary endpoint: Sustained Virologic Response at 72 weeks. Started Oct 2004; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00107653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107653.